PolyPeptide Group Balance Sheet Health
Financial Health criteria checks 5/6
PolyPeptide Group has a total shareholder equity of €381.2M and total debt of €101.5M, which brings its debt-to-equity ratio to 26.6%. Its total assets and total liabilities are €689.1M and €307.9M respectively.
Key information
26.6%
Debt to equity ratio
€101.46m
Debt
| Interest coverage ratio | n/a |
| Cash | €95.71m |
| Equity | €381.23m |
| Total liabilities | €307.86m |
| Total assets | €689.09m |
Recent financial health updates
No updates
Recent updates
Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
Mar 14
PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Mar 13PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 18Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Mar 23Financial Position Analysis
Short Term Liabilities: PPGN's short term assets (€326.6M) exceed its short term liabilities (€176.5M).
Long Term Liabilities: PPGN's short term assets (€326.6M) exceed its long term liabilities (€131.4M).
Debt to Equity History and Analysis
Debt Level: PPGN's net debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: PPGN's debt to equity ratio has reduced from 29.3% to 26.6% over the past 5 years.
Debt Coverage: PPGN's debt is well covered by operating cash flow (36%).
Interest Coverage: Insufficient data to determine if PPGN's interest payments on its debt are well covered by EBIT.